Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GDC-0980 + capecitabine
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GDC-0980 + capecitabine is a combination therapy under clinical investigation for advanced solid tumors, including colorectal cancer. GDC-0980 (apitolisib) is a small molecule dual inhibitor targeting class I phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), which are key components in the PI3K/AKT/mTOR pathway, a signaling axis frequently dysregulated in cancer. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), a widely used chemotherapeutic agent that inhibits thymidylate synthase, interfering with DNA synthesis and repair. The rationale for this combination is to simultaneously disrupt cancer cell survival signaling and impair DNA synthesis, thereby synergistically inhibiting tumor growth. This combination has been investigated in phase I clinical trials for advanced solid tumors and colorectal cancer[3].
- Other names
- apitolisib + capecitabine
02
Targets
PI3K (Phosphoinositide-3-kinase regulatory subunit 6)TS (Thymidylate synthase)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on GDC-0980 + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GDC-0980 + capecitabine.